224 related articles for article (PubMed ID: 15770338)
1. New trends in lipid management: eight cases to consider.
Smith DA
Mt Sinai J Med; 2005 Mar; 72(2):90-9. PubMed ID: 15770338
[TBL] [Abstract][Full Text] [Related]
2. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
Windler E
Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
[No Abstract] [Full Text] [Related]
3. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
Malloy MJ; Kane JP
Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
[No Abstract] [Full Text] [Related]
4. Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An affirmative view.
Crouch MA
J Fam Pract; 1988 Jun; 26(6):665-70. PubMed ID: 3379369
[No Abstract] [Full Text] [Related]
5. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
6. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
[No Abstract] [Full Text] [Related]
7. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
8. [Cholesterol: how and when to treat it?].
Masana Marín L
Med Clin (Barc); 1985 Oct; 85(10):423-5. PubMed ID: 4079497
[No Abstract] [Full Text] [Related]
9. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease.
Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM
Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017
[TBL] [Abstract][Full Text] [Related]
10. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
[TBL] [Abstract][Full Text] [Related]
11. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Broncel M; Balcerak M; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
[TBL] [Abstract][Full Text] [Related]
12. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
13. [Lipid therapy. Goal and use in prevention of coronary heart disease].
Windler E; Greten H
Internist (Berl); 1996 Dec; 37(12):1244-8. PubMed ID: 9081925
[No Abstract] [Full Text] [Related]
14. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hypercholesterolemia in patients with known coronary artery disease.
Schlant RC
Heart Dis Stroke; 1993; 2(5):373-6. PubMed ID: 8137037
[No Abstract] [Full Text] [Related]
16. Identifying all suspects: case studies.
Mason CM
Am J Manag Care; 2001 Aug; 7(9 Suppl):S307-16. PubMed ID: 11517817
[TBL] [Abstract][Full Text] [Related]
17. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
18. The management of hypercholesterolemia revisited.
Wiggins BS
Manag Care Interface; 2001 Jan; 14(1):58-66, 72. PubMed ID: 11214536
[TBL] [Abstract][Full Text] [Related]
19. [New results in the management of hypercholesterolemia].
Sármán B
Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867
[TBL] [Abstract][Full Text] [Related]
20. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
